Enclosed please find the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. Kindly take the information on record.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 0.6 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
GKB Ophthalmics reported mixed results for FY26. On a standalone basis, the company posted a net loss of Rs. 356.79 lakhs compared to a loss of Rs. 610.79 lakhs in FY25, with revenue declining 21.7% to Rs. 2,564.41 lakhs from Rs. 3,274.94 lakhs. However, consolidated results show a profit of Rs. 302.71 lakhs (vs loss of Rs. 707.92 lakhs in FY25) with revenue growing 36.8% to Rs. 14,906.35 lakhs, driven by the group's international subsidiaries. Exceptional items of Rs. 178.99 lakhs were recorded due to new Indian labour codes requiring additional gratuity and compensated absence liabilities. The company also completed voluntary winding up of its subsidiary GSV Ophthalmics Private Limited, realizing Rs. 11.70 crores from the investment. Statutory auditors issued an unqualified opinion confirming true and fair view of the financial statements.
The stock may see mixed investor reaction - the standalone revenue decline and losses are concerning, but the consolidated profit recovery and strong group revenue growth (37%) indicate underlying business strength through subsidiaries. The exceptional labour code charges represent a one-time hit.